Glucophage 500mg/tab
Glucophage 500mg/tab contains metformin hydrochloride as an active ingredient. It is used to control high blood glucose (hyperglycemia) in patients with type 2 diabetes, and diabetic ketoacidosis, an autoimmune disease in which the body is unable to produce insulin, resulting in excessive accumulation of glucose (glucose-galactose malabsorption). Metformin helps control the amount of glucose that is produced by the liver, and thereby slows down the rate of glucose absorption and absorption (glucose-dependent insulinotropic polypeptide-1 (GIP-1) agonist) action. The active ingredient in Metformin is metformin hydrochloride, and the inactive ingredients are: microcrystalline cellulose, pregelatinized starch, hypromellose, titanium dioxide, yellow ferric oxide, and red ferric oxide. Glucophage 500mg/tab works by decreasing the amount of glucose absorbed by the liver, which can be accomplished by increasing the amount of the insulin needed, decreasing the amount of glucose produced, and increasing the amount of metformin that is used in the diet. In a randomized, controlled study, metformin and sulfonylurea (Glucophage) were shown to be superior to sulfonylurea alone in treating hyperglycemia and in preventing diabetic ketoacidosis.
Glucophage 500mg/tab StrengthGlucophage 500mg/tab is used to control high blood glucose (hyperglycemia) in patients with type 2 diabetes, and diabetic ketoacidosis, an autoimmune disease in which the body cannot produce insulin, resulting in excessive accumulation of glucose (glucose-galactose malabsorption). Glucophage 500mg/tab works by decreasing the amount of glucose absorbed by the liver, which can be accomplished by increasing the amount of the insulin needed, decreasing the amount of glucose produced, and increasing metformin that is used in the diet.
Glucophage 500 mg is used for the treatment of type 2 diabetes as it contains metformin.Glucophage tablets are also used in preventing kidney damage.It is also taken during high blood pressure.
The Metformin 500 mg tablets are very beneficial in treating type 2 diabetes and ultimately reducing the risk of heart strokes.
Vomiting, nausea and rashing are observed as Glucophage side effects. These are temporary and are observed rarely.
-->
Glucophage 500mg Tab 10'S contains metformin, which belongs to the biguanide group of medicines used to treat type 2 diabetes mellitus (also called known as 'non-insulin-dependent diabetes').
Product Specifications and Features:
Safety Information:
Dosage:
Warnings:
Metformin is prescribed to treat the symptoms of type 2 diabetes (increased blood sugar levels), including reduced ability to control blood sugar. Metformin can also be used to treat type 2 diabetes when other diabetes medicines fail. Metformin is a biguanide, which means it works by lowering the amount of glucose synthesized from sugar in the blood.
The main drug of metformin is metformin hydrochloride. It is a biguanide, which means it works by blocking the action of a naturally occurring enzyme called HMG-CoA reductase, which is in charge of generating an increase in the amount of glucose synthesized from sugar in the blood.
Metformin is a biguanide, which means it works by blocking the action of a naturally occurring enzyme called HMG-CoA reductase, which is in charge of generating an increase in the amount of glucose synthesized from sugar in the blood.
Metformin is used to treat type 2 diabetes when other diabetes medicines fail.
Metformin is prescribed to treat type 2 diabetes when other diabetes medicines fail.
Metformin is also used to treat type 2 diabetes when other diabetes medicines fail.
Metformin, the active ingredient of Metformin Oral Solution, is a commonly prescribed drug for the management of type 2 diabetes mellitus (T2DM). Its mechanism of action involves inhibition of an enzyme system in the liver, which leads to decreased hepatic glucose production. Metformin inhibits metformin's hepatic enzyme, leading to decreased plasma glucose concentrations, thereby lowering glycemic control and reducing the risk of diabetes-related complications. The development of metformin in recent years has led to a rapid growth in research on metformin as a drug for diabetes management. The development of metformin as a therapy for diabetes has been fueled by a variety of factors, including its pharmacological properties (e.g., inhibition of glucose metabolism in the liver, increased glucose availability and excretion, reduced insulin resistance), the pharmacokinetics of metformin, its absorption and distribution in the body, and the presence of certain medical conditions such as hypertension, peripheral arterial disease, and diabetic ketoacidosis. Metformin is a lipophilic, crystalline drug. Its use in the treatment of diabetes mellitus is limited by a lack of research on its mechanism of action, its poor pharmacokinetics, and the risk of gastrointestinal side effects.
Metformin is a highly lipophilic drug that exhibits a wide spectrum of properties. It is rapidly absorbed, and its pharmacokinetics, pharmacodynamics, and pharmacokinetic parameters are very well described in literature. The drug is eliminated primarily by the kidneys in the form of a soluble fraction, but its pharmacokinetics and pharmacodynamics are poorly understood. The most well-studied metabolic pathway of metformin is the gluconeogenesis pathway, which is also known as gluconeogenesis. Metformin is a potent inhibitor of the gluconeogenesis pathway, leading to reduced hepatic glucose production and increased insulin sensitivity in the liver. This mechanism of action has been proposed to contribute to the treatment of diabetes mellitus by decreasing the amount of insulin produced by the liver, thereby decreasing the risk of developing diabetes-related complications. The potential benefits of metformin for the treatment of diabetes mellitus include the reduction of the risk of developing diabetes-related complications, improved glycemic control, and the prevention of complications associated with the metabolic syndrome. However, the development of metformin as a therapy for diabetes mellitus has been fueled by a variety of factors, including its pharmacological properties (e.g., inhibition of glucose metabolism in the liver, increased glucose availability and excretion, reduced insulin resistance), the pharmacokinetics of metformin, its absorption and distribution in the body, and the presence of certain medical conditions such as hypertension, peripheral arterial disease, and diabetic ketoacidosis. Metformin is a lipophilic drug that exhibits a wide spectrum of properties. Metformin is a highly lipophilic, crystalline drug that exhibits a wide spectrum of properties. Metformin is a lipophilic, crystalline drug that exhibits a wide spectrum of properties. It is rapidly absorbed, and its pharmacokinetics, pharmacodynamics, and pharmacokinetic parameters are well described in literature.
Glucophage® (metformin) is a widely used drug for the treatment of Type 2 diabetes mellitus. It belongs to the class of drugs known as HMG-CoA reductase inhibitors. Its market sales have been steadily increasing over the past few years due to its significant impact on diabetes management.
The growth of the Metformin market is driven by several factors:
Increasing prevalence of Type 2 diabetes: In recent years, the global prevalence of Type 2 diabetes has risen significantly. The number of adults living with Type 2 diabetes is expected to reach approximately 10.4 million by 2030, growing from 4.7 million in 2008 in the United States to 6.7 million by 2030 in Japan. This increase is attributed to the increasing prevalence of Type 2 diabetes in Europe, North America, and China.
Growing awareness of Type 2 diabetes: The growing incidence of Type 2 diabetes is a major driver of the Metformin market, contributing to its high demand. Diabetes awareness campaigns have been launched in over 100 countries, with more than 15 million individuals on the market each year. The growing awareness about Type 2 diabetes is also contributing to the market growth.
The rising prevalence of Type 2 diabetes: The prevalence of Type 2 diabetes is rising in more than 80 countries and regions, driven by various factors, including rising urbanization, a growing population, and increased healthcare expenditure. This trend is expected to continue throughout the rest of the world, contributing to the market growth.
Growing awareness about the importance of healthy living for people living with Type 2 diabetes: The growing awareness about the importance of healthy living, including a well-rounded lifestyle, is driving market growth. This is due to the growing prevalence of Type 2 diabetes, which is a chronic condition that requires ongoing management and support. This awareness has led to a surge in demand for metformin and other diabetes medications.
The rising prevalence of Type 2 diabetes in the global population is a significant driver of market growth. The increasing number of adults living with this condition is expected to continue, driving the demand for medications like Metformin and other diabetes medicines.
The global Metformin market is projected to reach $1.5 billion by 2030, with a projected annual growth rate (GBR) of 8.9% from 2024 to 2030. This growth is attributed to the rising prevalence of Type 2 diabetes, which is a chronic condition that requires ongoing management and support. The rising awareness about diabetes and its treatment has also led to a surge in healthcare expenditure, contributing to the market growth. As a result, the demand for medications like metformin and other diabetes medicines has increased, driving market growth.
Several factors are driving the demand for Metformin, including:
Growing urbanization: A growing population, particularly in urban areas, is contributing to the increasing prevalence of Type 2 diabetes. The rising prevalence of Type 2 diabetes is associated with a growing urban population, increasing traffic, and the increasing prevalence of overweight and obesity.
Growing population: The growing incidence of Type 2 diabetes is projected to continue, leading to a higher demand for metformin. As a result, the demand for metformin and other diabetes medications is expected to increase, driving market growth.
Healthcare expenditure: The growing population, particularly in urban areas, is expected to increase the demand for metformin.
Healthcare resource: The rising prevalence of Type 2 diabetes is related to an aging population, which can lead to more frequent visits to healthcare facilities. The increasing geriatric population is also contributing to the increasing demand for metformin.
Access to healthcare: The increasing prevalence of Type 2 diabetes is a major driver of the Metformin market, as it is a type of chronic disease that requires ongoing management and support.
The increasing prevalence of Type 2 diabetes in the global population is a significant driver of market growth.
Stade de France Pharmacy